Silencing overexpression of FXYD3 protein in breast cancer cells amplifies effects of doxorubicin and γ-radiation on Na+/K+-ATPase and cell survival Chia-Chi LiuRachel TehHelge H. Rasmussen Preclinical study 06 January 2016 Pages: 203 - 213
Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer Lars JønsonLise B. AhlbornThomas V. O. Hansen Preclinical study 06 January 2016 Pages: 215 - 222
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach Anton SafonovShiyi WangChristos Hatzis Preclinical study 09 January 2016 Pages: 223 - 234
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl Jennifer L. DineCiara C. O’SullivanStanley Lipkowitz Preclinical study 12 January 2016 Pages: 235 - 251
Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA Francisco QuilesMireia MenéndezConxi Lázaro Preclinical Study 16 January 2016 Pages: 253 - 260
Telomeric G-quadruplex-forming DNA fragments induce TLR9-mediated and LL-37-regulated invasion in breast cancer cells in vitro Johanna M. TuomelaJouko A. SandholmKatri S. Selander Preclinical study 18 January 2016 Pages: 261 - 271
Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results Anna G. SoraceC. Chad QuarlesThomas E. Yankeelov Preclinical study 20 January 2016 Pages: 273 - 284
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines Ana BaracFilipa LynceClaudine Isaacs Clinical trial 09 January 2016 Pages: 285 - 293
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer Joanne L. BlumAnthony GonçalvesSuzette Delaloge Clinical trial 09 January 2016 Pages: 295 - 302
Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling Walter M. GregoryChristopher J. TwelvesDavid A. Cameron Clinical trial Open access 19 January 2016 Pages: 303 - 311
Variants of FGFR2 and their associations with breast cancer risk: a HUGE systematic review and meta-analysis Fei CuiDuoguang WuMinghui Wang Epidemiology 04 January 2016 Pages: 313 - 335
Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting Terry NgSasha MazzarelloMark Clemons Epidemiology 05 January 2016 Pages: 337 - 344
Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival H. FrydenbergI. ThuneA. McTiernan Epidemiology 06 January 2016 Pages: 345 - 354
Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortium Edward A. Ruiz-NarváezStephen A. HaddadJulie R. Palmer Epidemiology 07 January 2016 Pages: 355 - 363
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study Joanne KotsopoulosTomasz HuzarskiSteven A. Narod Epidemiology 16 January 2016 Pages: 365 - 373
A two-stage approach to genetic risk assessment in primary care Swati BiswasPhilamer AtienzaGiovanni Parmigiani Epidemiology 19 January 2016 Pages: 375 - 383
Adolescent intake of animal fat and red meat in relation to premenopausal mammographic density Kimberly A. BertrandRosemarie A. BurianRulla M. Tamimi Epidemiology 20 January 2016 Pages: 385 - 393
Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence Joel M. BrothersKelley M. KidwellN. Lynn Henry Epidemiology 21 January 2016 Pages: 395 - 403
Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study Jeffrey S. RossLaurie M. GayPhilip J. Stephens Brief Report 13 January 2016 Pages: 405 - 413
